A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

On Jan. 26, the FDA’s vac­cines ad­comm will meet to dis­cuss the fu­ture of Covid-19 boost­er shots and vari­ant strain se­lec­tion mov­ing for­ward, and CBER … ...

What can a cough say about a pa­tient’s ill­ness? Quite a bit, ac­cord­ing to Re­sApp Health — and Pfiz­er’s lis­ten­ing.

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther ...

Months af­ter No­vavax cel­e­brat­ed its first prof­itable quar­ter as a com­mer­cial com­pa­ny, the Gaithers­burg, MD-based com­pa­ny is back in the red.

De­spite Ugur Sahin’s calls for calm over the Omi­cron vari­ant — mak­ing a much more mea­sured ap­peal than Mod­er­na CEO Stéphane Ban­cel — the BioN­Tech chief is … ...

In a sign of its grow­ing com­mit­ment to the con­ti­nent, Mod­er­na will sup­ply up to 110 mil­lion dos­es of its Covid-19 vac­cine to the African … ...

When Sofinno­va Part­ners un­veiled its $540 mil­lion crossover fund ear­li­er this year, the Paris-based pow­er VC play­er tout­ed its lead­ing role in pro­vid­ing late … ...

John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 15 years. Aside from his ...

If any­one wants a les­son in the val­ue of be­ing first-in-class and best-in-class in the drug busi­ness, pick up a copy of Pfiz­er’s quar­ter­ly re­port … ...

Af­ter Pfiz­er and BioN­Tech scored the FDA’s emer­gency use au­tho­riza­tion for their mR­NA-based Covid-19 shot late last week, hopes are high that one or … ...